HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection

AIDS

Volumn 28, Issue 1, 2014, Pages 49-58

  Wheeler, Amber L ^a,b   Scherzer, Rebecca ^a,b   Lee, Daniel ^c   Delaney, Joseph A C ^d   Bacchetti, Peter ^a   Shlipak, Michael G ^a,b   Sidney, Stephen ^e   Grunfeld, Carl ^a,b   Tien, Phyllis C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e DIVISION OF RESEARCH   (United States)

Author keywords

Cardiovascular disease; Hepatitis C virus infection; HIV infection; Lipoproteins

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MALE; MIDDLE AGED; MIXED INFECTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; WAIST HIP RATIO; ADOLESCENT; BLOOD; CHEMISTRY; COMPLICATION; PARASITOLOGY; PLASMA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COINFECTION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PLASMA; YOUNG ADULT;

EID: 84892365212     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000026     Document Type: Article

References (43)

1. Bucher HC, Richter W, Glass TR, Magenta L, Wang Q, Cavassini M, et al. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012; 60:135-142.
2. Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207:524-529.
3. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49:225-232.
4. Roed T, Lebech AM, Kjaer A, Weis N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging 2012; 32:421-430.
5. Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011; 4:425-432.
6. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11:462-468.
7. Tien PC, Schneider MF, Cole SR, Cohen MH, Glesby MJ, Lazar J, et al. Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the Women's Interagency HIV study. AIDS 2009; 23:1781-1784.
8. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76:1423-1427.
9. Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C. Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis 2012; 222:274-277.
10. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in noninsulin-dependent diabetes. Arterioscler Thromb 1992; 12:1496-1502.
11. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
12. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004; 6:381-387.
13. Hsia J, Otvos JD, Rossouw JE, Wu L, Wassertheil-Smoller S, Hendrix SL, et al. Lipoprotein particle concentrations may explain the absence of coronary protection in the Women's Health Initiative Hormone trials. Arterioscler Thromb Vasc Biol 2008; 28:1666-1671.
14. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23:97-104.
15. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52:453-462.
16. Blake GJ. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106:1930-1937.
17. Kuller LH, Grandits G, Cohen JD, Neaton JD, Prineas R, Multiple Risk Factor Intervention Trial Research G. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2007; 195:122-128.
18. El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPICNorfolk Prospective Population Study. J Am Coll Cardiol 2007; 49:547-553.
19. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007; 192:211-217.
20. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002; 90:89-94.
21. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002; 48:171-180.
22. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multiethnic Study of Atherosclerosis). J Am Coll Cardiol 2012; 60:508-516.
23. Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, Henry K, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010; 201:285-292.
24. Tien PC, Schneider MF, Cox C, Cohen M, Karim R, Lazar J, et al. HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study. AIDS 2010; 24:2809-2817.
25. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860-869.
26. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-1849.
27. Hastie T, Tibshirani R. Generalized additive models (Chapman & Hall/CRC Monographs on Statistics & Applied Probability). New York: Chapman and Hall; 1990.
28. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005; 111:3465-3472.
29. Koenker R, Hallock K. Quantile regression. J Economic Perspectives 2001; 15:143-156.
30. Floris-Moore M, Howard AA, Lo Y, SchoenbaumEE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS 2007; 21:479-491.
31. Patroni A, Torti C, Tomasoni L, Roldan EQ, Bertelli D, Puoti M, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials 2002; 3:451-461.
32. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:245-250.
33. Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-148.
34. Barter P, Kastelein J, Nunn A, Hobbs R, Future Forum Editorial B. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003; 168:195-211.
35. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3:144-153.
36. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:1046-1053.
37. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113:1556-1563.
38. Grunfeld C. Dyslipidemia and its treatment in HIV infection. Top HIV Med 2010; 18:112-118.
39. Shimizu Y, Hishiki T, Ujino S, Sugiyama K, Funami K, Shimotohno K. Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. Curr Opin Virol 2011; 1:19-26.
40. Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46:411-419.
41. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96:12766-12771.
42. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of coreceptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003; 278:41624-41630.
43. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012; 55:998-1007.